Article
ESMO: Novartis posts data from failed spartalizumab phase 3, reaffirms commitment to PD-1 combos
Rating:
0.0
Views:
102
Likes:
1
Library:
1
Novartis has shared data from the failed phase 3 melanoma trial of its anti-PD-1 checkpoint inhibitor spartalizumab. The readout showed adding spartalizumab to Tafinlar and Mekinist achieved similar results to an earlier assessment of a similar combination but on this occasion the difference fell short of statistical significance.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value